Novavax, Inc. (NVAX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.89: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum.
Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19 vaccine (Nuvaxovid) is now fully commercialized by Sanofi under a 2024 collaboration agreement; Novavax earns milestones, royalties, and supply revenue.... Read more
Sell if holding. Engine safety override at $8.89: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Novavax, Inc.
Latest news
- NEWS U.S. FDA Advisers Vote In Favor Of Recommending Covid Vaccines Target JN.1 Lineage XFG Variant For 2026-27 Campaign — benzinga May 28, 2026 positive
- NEWS Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb — benzinga May 11, 2026 positive
- NEWS What's Going On With Novavax Stock On Friday? — benzinga May 8, 2026 neutral
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS TD Cowen Maintains Hold on Novavax, Raises Price Target to $9 — benzinga May 6, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartySanofi (COVID-19 vaccine commercialization)10-K Item 1: 'In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™)'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 8.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -14.7%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.89: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.26. Score 5.2/10, moderate confidence.
Take-profit target: $12.28 (+38.3% upside). Prior stop was $8.26. Stop-loss: $8.26.
Concentration risk — Counterparty: Sanofi (COVID-19 vaccine commercialization); Quality below floor (2.8 < 4.0).
Novavax, Inc. trades at a P/E of N/A (forward -16.4). TrendMatrix value score: 7.6/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19...
Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19 vaccine (Nuvaxovid) is now fully commercialized by Sanofi under a 2024 collaboration agreement; Novavax earns milestones, royalties, and supply revenue. Matrix-M is also licensed to Serum Institute of India (R21 malaria vaccine), Takeda (Japan), and Pfizer (January 2026 agreement).